British medical journal The Lancet published a report on the phase 2 results of COVAXIN. It said that the vaccine has better reactogenicity and safety outcomes. There was no threat to life either, it added, as per a report in ANI. Also, it was effective even 3 months later.??
"The reactogenicity assessments reported in this study were substantially better in the phase 2 trial than the phase 1 trial and other trials with a placebo group. Additionally, the proportion of participants reporting adverse events in the phase 2 trial were lower than in the phase 1 trial," said the report said.
"Most common adverse event in the phase 2 trial was pain at the injection site, followed by headache, fatigue, and fever. No severe or life-threatening (i.e., grade 4 and 5) solicited adverse events were reported. No significant differences in safety were observed between the two groups," it added.?
"In the phase 2 trial, the Bharat Biotech vaccine showed better reactogenicity and safety outcomes, and enhanced humoral and cell-mediated immune responses compared with the phase 1 trial," it went on to say?
No COVID cases were reported in either group of the phase 2 trial.?
In India, over 1 crore are affected while over 1.5 lakh have died. Worldwide, nearly 12 crore are affected while more than 26 lakh have died.